Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Apellis Pharmaceuticals (APLS) Return on Invested Capital (2021 - 2025)

Apellis Pharmaceuticals filings provide 5 years of Return on Invested Capital readings, the most recent being 0.01% for Q4 2025.

  • For the quarter ending Q4 2025, Return on Invested Capital rose 76.0% year-over-year to 0.01%, compared with a TTM value of 0.01% through Dec 2025, up 76.0%, and an annual FY2025 reading of 0.01%, up 83.0% over the prior year.
  • Return on Invested Capital hit 0.01% in Q4 2025 for Apellis Pharmaceuticals, down from 0.25% in the prior quarter.
  • The five-year high for Return on Invested Capital was 0.25% in Q3 2025, with the low at 7.6% in Q4 2021.
  • Median Return on Invested Capital over the past 5 years was 0.97% (2025), compared with a mean of 1.36%.
  • The sharpest move saw Return on Invested Capital surged 702bps in 2022, then plummeted -186bps in 2023.
  • Year by year, Return on Invested Capital stood at 7.6% in 2021, then skyrocketed by 92bps to 0.57% in 2022, then plummeted by -324bps to 2.43% in 2023, then skyrocketed by 69bps to 0.75% in 2024, then soared by 101bps to 0.01% in 2025.
  • According to Business Quant data, Return on Invested Capital over the past three periods came in at 0.01%, 0.25%, and 1.22% for Q4 2025, Q3 2025, and Q2 2025 respectively.